Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298227 | 0.86 | NPC1 (0.72) | KDM4EGAANPC1RAB9ARECQL | |
| SCHEMBL26132980 | 0.83 | RAB9A (0.57) | KDM4ENPC1RAB9ARECQLTDP1 | |
| SCHEMBL8489668 | 0.82 | NPC1 (0.56) | KDM4ENPC1RAB9ARECQLTDP1 | |
| SCHEMBL310065 | 0.82 | NPC1 (0.56) | KDM4ENPC1RAB9ARECQLTDP1 | |
| SCHEMBL10263950 | 0.82 | NPC1 (0.56) | KDM4ENPC1RAB9ARECQLTDP1 | |
| SCHEMBL11445653 | 0.81 | KDM4E (0.48) | KDM4EGAANPC1RAB9ARECQL | |
| SCHEMBL28436127 | 0.81 | NPC1 (0.54) | KDM4ENPC1RAB9ARECQLTDP1 | |
| SCHEMBL23861126 | 0.80 | ALDH1A1 (0.62) | KDM4EGAANPC1RAB9ARECQL | |
| SCHEMBL1141627 | 0.80 | TDP1 (0.60) | KDM4EGAANPC1RAB9ARECQL | |
| SCHEMBL30072726 | 0.80 | TDP1 (0.60) | KDM4EGAANPC1RAB9ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| EP-2162454-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | KDM4E 790/4885GAA 1644/4885NPC1 2713/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | KDM4E 790/4885GAA 1644/4885NPC1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.